{"transactions":[{"id":4620270,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Award","published_at":"2026-09-17T00:01:16.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":471,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant."}],"balance_after":471,"derivative":{"underlying":"Common Stock","underlying_shares":471},"source":{"system":"sec-edgar","filing":"0001711279-26-000060","document":"wk-form4_1789603273.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000060/wk-form4_1789603273.xml","form_type":"4"}},{"id":4620269,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-17T00:01:16.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":1187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant."}],"balance_after":1187,"derivative":{"exercise_price":340.03,"expiration_date":"2036-09-13","underlying":"Common Stock","underlying_shares":1187},"source":{"system":"sec-edgar","filing":"0001711279-26-000060","document":"wk-form4_1789603273.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000060/wk-form4_1789603273.xml","form_type":"4"}},{"id":867437,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T23:28:41.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":2373,"price":276.1665,"value":655343.1045,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades ranging from $276 to $276.4924. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":73293,"source":{"system":"sec-edgar","filing":"0001711279-26-000023","document":"wk-form4_1772580519.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000023/wk-form4_1772580519.xml","form_type":"4"}},{"id":867436,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T23:28:41.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":9430,"price":275.4487,"value":2597481.241,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $275 to $275.986. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":75666,"source":{"system":"sec-edgar","filing":"0001711279-26-000023","document":"wk-form4_1772580519.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000023/wk-form4_1772580519.xml","form_type":"4"}},{"id":879737,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":false,"shares":37895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F24","text":"The options vested ratably over a four-year period beginning on November 10, 2016."}],"balance_after":0,"derivative":{"exercise_price":2.46,"expiration_date":"2026-11-09","underlying":"Common Stock","underlying_shares":37895},"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879736,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-26","kind":"sale","planned":true,"acquired":false,"shares":2638,"price":276.3152,"value":728919.4976,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F23","text":"The transaction was executed in multiple trades ranging from $276 to $276.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":85096,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879735,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-26","kind":"sale","planned":true,"acquired":false,"shares":5103,"price":275.2812,"value":1404759.9636,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F22","text":"The transaction was executed in multiple trades ranging from $275 to $275.9782. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":87734,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879734,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":700,"price":275,"value":192500.0,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F21","text":"The transaction was executed in a single trade."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":92837,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879733,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":2425,"price":274.8977,"value":666626.9225,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F20","text":"The transaction was executed in multiple trades ranging from $274.59 to $275. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":93537,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879732,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":930,"price":269.5013,"value":250636.209,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The transaction was executed in multiple trades ranging from $269.1641 to $269.78. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":95962,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879731,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":1674,"price":268.666,"value":449746.884,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The transaction was executed in multiple trades ranging from $268.0725 to $269.0705. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":96892,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879730,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":1891,"price":267.37,"value":505596.67,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The transaction was executed in multiple trades ranging from $267.0631 to $268.0275. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":98566,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879729,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":4339,"price":266.6234,"value":1156878.9326,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The transaction was executed in multiple trades ranging from $266.06 to $267.0511. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":100457,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879728,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":1604,"price":265.5356,"value":425919.1024,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The transaction was executed in multiple trades ranging from $265.04 to $266. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":104796,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879727,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":900,"price":264.5956,"value":238136.04,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The transaction was executed in multiple trades ranging from $264.01 to $264.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":106400,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879726,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":62,"price":263.0511,"value":16309.1682,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The transaction was executed in multiple trades ranging from $262.9496 to $263.1269.  The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":107300,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879725,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":373,"price":271.0938,"value":101117.9874,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The transaction was executed in multiple trades ranging from $270.650 to $271.610.  The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879724,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":370,"price":269.8282,"value":99836.434,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The transaction was executed in multiple trades ranging from $269.610 to $270.140.  The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":373,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879723,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":3963,"price":268.9689,"value":1065923.7507,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The transaction was executed in multiple trades ranging from $268.540 to $269.530.  The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":743,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879722,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":6671,"price":268.0377,"value":1788079.4967,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The transaction was executed in multiple trades ranging from $267.520 to $268.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":4706,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879721,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":11673,"price":266.9674,"value":3116310.4602,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades ranging from $266.520 to $267.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":11377,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879720,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":8986,"price":266.1791,"value":2391885.3926,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $265.520 to $266.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":23050,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879719,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":3557,"price":265.0768,"value":942878.1776,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades ranging from $264.520 to $265.495. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":32036,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879718,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":1733,"price":264.1246,"value":457727.9318,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades ranging from $263.510 to $264.450. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":35593,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879717,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":569,"price":262.907,"value":149594.083,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $262.480 to $263.400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":37326,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":879716,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T23:49:48.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":true,"shares":37895,"price":2.46,"value":93221.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."}],"balance_after":37895,"source":{"system":"sec-edgar","filing":"0001711279-26-000021","document":"wk-form4_1772149785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000021/wk-form4_1772149785.xml","form_type":"4"}},{"id":1099294,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-30T22:14:55.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were awarded on June 30, 2025 and vest in equal monthly tranches over a one-year period."}],"balance_after":5000,"derivative":{"exercise_price":137.46,"expiration_date":"2035-06-30","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001711279-25-000057","document":"wk-form4_1751321689.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000057/wk-form4_1751321689.xml","form_type":"4"}},{"id":1465831,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T23:34:51.000Z","date":"2024-06-30","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were awarded on June 30, 2024 and vest in equal monthly tranches over a one-year period."}],"balance_after":5000,"derivative":{"exercise_price":183.64,"expiration_date":"2034-06-30","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001711279-24-000029","document":"wk-form4_1719876885.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000029/wk-form4_1719876885.xml","form_type":"4"}},{"id":1839753,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-03T20:20:57.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":6800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were awarded on June 30, 2023 and vest in equal monthly tranches over a one-year period."}],"balance_after":6800,"derivative":{"exercise_price":117.4,"expiration_date":"2033-06-30","underlying":"Common Stock","underlying_shares":6800},"source":{"system":"sec-edgar","filing":"0001711279-23-000051","document":"wk-form4_1688415647.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000051/wk-form4_1688415647.xml","form_type":"4"}},{"id":1860609,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:03:48.000Z","date":"2023-06-09","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":128.5262,"value":1285262.0,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The transaction was executed in multiple trades ranging from $127.715 to $129.6100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":107362,"source":{"system":"sec-edgar","filing":"0001711279-23-000046","document":"wk-form4_1686351820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000046/wk-form4_1686351820.xml","form_type":"4"}},{"id":1860608,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:03:48.000Z","date":"2023-06-09","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":128.8375,"value":644187.5,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades ranging from $128.5000 to $129.4800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":117362,"source":{"system":"sec-edgar","filing":"0001711279-23-000046","document":"wk-form4_1686351820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000046/wk-form4_1686351820.xml","form_type":"4"}},{"id":1860607,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:03:48.000Z","date":"2023-06-09","kind":"sale","planned":false,"acquired":false,"shares":3935,"price":129.2943,"value":508773.0705,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $129.0000 to $129.7400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":122362,"source":{"system":"sec-edgar","filing":"0001711279-23-000046","document":"wk-form4_1686351820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000046/wk-form4_1686351820.xml","form_type":"4"}},{"id":1860606,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:03:48.000Z","date":"2023-06-08","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":127.8612,"value":639306.0,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades ranging from $127.7000 to $128.44. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":126297,"source":{"system":"sec-edgar","filing":"0001711279-23-000046","document":"wk-form4_1686351820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000046/wk-form4_1686351820.xml","form_type":"4"}},{"id":1860605,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:03:48.000Z","date":"2023-06-08","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":127.9584,"value":1279584.0,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":131297,"source":{"system":"sec-edgar","filing":"0001711279-23-000046","document":"wk-form4_1686351820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000046/wk-form4_1686351820.xml","form_type":"4"}},{"id":1860604,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:03:48.000Z","date":"2023-06-08","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":127.958,"value":639790.0,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":141297,"source":{"system":"sec-edgar","filing":"0001711279-23-000046","document":"wk-form4_1686351820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000046/wk-form4_1686351820.xml","form_type":"4"}},{"id":1860603,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:03:48.000Z","date":"2023-06-08","kind":"sale","planned":false,"acquired":false,"shares":5388,"price":128.7335,"value":693616.098,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades ranging from $128.5000 to $129.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":146297,"source":{"system":"sec-edgar","filing":"0001711279-23-000046","document":"wk-form4_1686351820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000046/wk-form4_1686351820.xml","form_type":"4"}},{"id":1860602,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:03:48.000Z","date":"2023-06-08","kind":"sale","planned":false,"acquired":false,"shares":1073,"price":129.0218,"value":138440.3914,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $129.0000 to $129.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":151685,"source":{"system":"sec-edgar","filing":"0001711279-23-000046","document":"wk-form4_1686351820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000046/wk-form4_1686351820.xml","form_type":"4"}},{"id":1860601,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:03:48.000Z","date":"2023-06-08","kind":"sale","planned":false,"acquired":false,"shares":4604,"price":127.9578,"value":589117.7112,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":152758,"source":{"system":"sec-edgar","filing":"0001711279-23-000046","document":"wk-form4_1686351820.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000046/wk-form4_1686351820.xml","form_type":"4"}},{"id":1874477,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-05-30T18:00:28.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":86762,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual\nMeeting of stockholders that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":86762,"derivative":{"exercise_price":4.81,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":86762},"source":{"system":"sec-edgar","filing":"0001209191-23-032970","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919123032970/doc4.xml","form_type":"4"}},{"id":1881156,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-23T20:20:34.000Z","date":"2023-05-19","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":95.0237,"value":4751185.0,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 12, 2022 and will terminate on September 11, 2023 and contemplates sales of 50,000 shares with a limit price of $95.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $95.0000 to $95.3800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":157362,"source":{"system":"sec-edgar","filing":"0001711279-23-000042","document":"wf-form4_168487321853185.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000042/wf-form4_168487321853185.xml","form_type":"4"}},{"id":1896751,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-11T20:30:54.000Z","date":"2023-05-09","kind":"sale","planned":true,"acquired":false,"shares":17100,"price":90.7356,"value":1551578.76,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 12, 2022 and will terminate on September 11, 2023 and contemplates sales of 25,000 shares with a limit price of $90.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $90.0000 to $91.1350. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":207362,"source":{"system":"sec-edgar","filing":"0001711279-23-000035","document":"wf-form4_168383702435561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000035/wf-form4_168383702435561.xml","form_type":"4"}},{"id":1915631,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-21T20:10:57.000Z","date":"2023-04-19","kind":"sale","planned":true,"acquired":false,"shares":7900,"price":90.3156,"value":713493.24,"ownership":{"direct":false,"nature":"Directly beneficially owned by Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 12, 2022 and will terminate on September 11, 2023 and contemplates sales of 25,000 shares with a limit price of $90.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $90.0000 to $90.3650. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":224462,"source":{"system":"sec-edgar","filing":"0001711279-23-000023","document":"wf-form4_168210784238261.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000023/wf-form4_168210784238261.xml","form_type":"4"}},{"id":2151832,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-23T16:25:06.000Z","date":"2022-09-21","kind":"purchase","acquired":true,"shares":475000,"price":5.02,"value":2384500.0,"ownership":{"direct":false,"nature":"By Alta Partners NextGen Fund I, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reports the purchase of shares in the underwritten public offering of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Alta Partners NextGen Fund I, L.P. (\"APNG I\"). Alta Partners NextGen Fund I Management, LLC (\"APNG I Management\") is the general partner of APNG I. The Reporting Person is one of three managing directors of APNG I Management and, as such, has voting and investment control with respect to the shares held by APNG I. The Reporting Person disclaims beneficial ownership of all shares held by APNG I, except to the extent of his pecuniary interest therein."}],"balance_after":2546147,"source":{"system":"sec-edgar","filing":"0001209191-22-051141","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919122051141/doc4.xml","form_type":"4"}},{"id":2217363,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-01T20:12:23.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":6800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were awarded on June 30, 2022 and vest in equal monthly tranches over a one-year period."}],"balance_after":6800,"derivative":{"exercise_price":65.66,"expiration_date":"2032-06-30","underlying":"Common Stock","underlying_shares":6800},"source":{"system":"sec-edgar","filing":"0001711279-22-000038","document":"wf-form4_165670631803960.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127922000038/wf-form4_165670631803960.xml","form_type":"4"}},{"id":2253000,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-05-27T16:16:50.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":99590,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual\nMeeting of stockholders that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":99590,"derivative":{"exercise_price":2.62,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":99590},"source":{"system":"sec-edgar","filing":"0001209191-22-032520","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919122032520/doc4.xml","form_type":"4"}},{"id":2416782,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-02T21:38:56.000Z","date":"2021-12-30","kind":"gift","acquired":false,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person transferred these shares of common stock to a charitable trust, over which the Reporting Person has no pecuniary interest or investment control."}],"balance_after":232362,"source":{"system":"sec-edgar","filing":"0001062993-22-002225","document":"form5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000106299322002225/form5.xml","form_type":"5"}},{"id":2473558,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-14T21:11:44.000Z","date":"2021-12-10","kind":"sale","acquired":false,"shares":100000,"price":70.5,"value":7050000.0,"ownership":{"direct":false,"nature":"By Alta Bioequities L.P"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 3, 2021, Krystal Biotech, Inc. (the \"Company\"), closed the previously announced underwritten public offering of 2,666,667 shares of its common stock, at a public offering price of $75.00 per share. The Company and certain selling stockholders granted the underwriters a 30-day option to purchase up to an additional 400,000 shares of the Company's common stock offered in the public offering, which includes up to 200,000 shares from the selling stockholders. The underwriters exercised the option and on December 10, 2021, purchased the 400,000 shares of the Company's common stock, including 100,000 shares of the Company's common stock from Alta Bioequities, L.P., a selling stockholder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC and may be deemed to have voting and investment power over the shares owned by Alta Bioequities, L.P."}],"balance_after":266362,"source":{"system":"sec-edgar","filing":"0000899243-21-048122","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000089924321048122/doc4.xml","form_type":"4"}},{"id":2542273,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-10-14T16:28:06.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":7700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next Annual Meeting that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":7700,"derivative":{"exercise_price":99.83,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":7700},"source":{"system":"sec-edgar","filing":"0001209191-21-060467","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919121060467/doc4.xml","form_type":"4"}},{"id":2566273,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":135395,"kind":"organization","name":"Alta Partners NextGen Fund II Management, LLC","position":1,"cik":"0001881002","reported_name":"Alta Partners NextGen Fund II Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135396,"kind":"organization","name":"Alta Partners NextGen Fund II, L.P.","position":2,"cik":"0001768658","reported_name":"Alta Partners NextGen Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":3,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":4,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-09-17T20:47:41.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":255160,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alta Partners NextGen Fund II, L.P. (the \"APNG II\"). The shares directly held by APNG II are indirectly held by Alta Partners NextGen Fund II Management, LLC (\"APNG II Management\"), which is the general partner of APNG II. The individual managing directors of APNG II Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG II Management exercise shared voting and investment control with respect to the shares held by APNG II. APNG II Management, Mr. Hudson and Mr. Janney disclaim beneficial ownership of all shares held by APNG II, except to the extent of its or their respective pecuniary interests therein. Mr. More is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":662752},"source":{"system":"sec-edgar","filing":"0000899243-21-036429","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036429/doc4.xml","form_type":"4"}},{"id":2566272,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":135395,"kind":"organization","name":"Alta Partners NextGen Fund II Management, LLC","position":1,"cik":"0001881002","reported_name":"Alta Partners NextGen Fund II Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135396,"kind":"organization","name":"Alta Partners NextGen Fund II, L.P.","position":2,"cik":"0001768658","reported_name":"Alta Partners NextGen Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":3,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":4,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-09-17T20:47:41.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":1212122,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alta Partners NextGen Fund II, L.P. (the \"APNG II\"). The shares directly held by APNG II are indirectly held by Alta Partners NextGen Fund II Management, LLC (\"APNG II Management\"), which is the general partner of APNG II. The individual managing directors of APNG II Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG II Management exercise shared voting and investment control with respect to the shares held by APNG II. APNG II Management, Mr. Hudson and Mr. Janney disclaim beneficial ownership of all shares held by APNG II, except to the extent of its or their respective pecuniary interests therein. Mr. More is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3148365},"source":{"system":"sec-edgar","filing":"0000899243-21-036429","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036429/doc4.xml","form_type":"4"}},{"id":2566271,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":135395,"kind":"organization","name":"Alta Partners NextGen Fund II Management, LLC","position":1,"cik":"0001881002","reported_name":"Alta Partners NextGen Fund II Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135396,"kind":"organization","name":"Alta Partners NextGen Fund II, L.P.","position":2,"cik":"0001768658","reported_name":"Alta Partners NextGen Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":3,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":4,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T20:47:41.000Z","date":"2021-09-17","kind":"purchase","acquired":true,"shares":156250,"price":16,"value":2500000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alta Partners NextGen Fund II, L.P. (the \"APNG II\"). The shares directly held by APNG II are indirectly held by Alta Partners NextGen Fund II Management, LLC (\"APNG II Management\"), which is the general partner of APNG II. The individual managing directors of APNG II Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG II Management exercise shared voting and investment control with respect to the shares held by APNG II. APNG II Management, Mr. Hudson and Mr. Janney disclaim beneficial ownership of all shares held by APNG II, except to the extent of its or their respective pecuniary interests therein. Mr. More is a director of the Issuer and files separate Section 16 reports."}],"balance_after":4080296,"source":{"system":"sec-edgar","filing":"0000899243-21-036429","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036429/doc4.xml","form_type":"4"}},{"id":2566270,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":135395,"kind":"organization","name":"Alta Partners NextGen Fund II Management, LLC","position":1,"cik":"0001881002","reported_name":"Alta Partners NextGen Fund II Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135396,"kind":"organization","name":"Alta Partners NextGen Fund II, L.P.","position":2,"cik":"0001768658","reported_name":"Alta Partners NextGen Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":3,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":4,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T20:47:41.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":3811117,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alta Partners NextGen Fund II, L.P. (the \"APNG II\"). The shares directly held by APNG II are indirectly held by Alta Partners NextGen Fund II Management, LLC (\"APNG II Management\"), which is the general partner of APNG II. The individual managing directors of APNG II Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG II Management exercise shared voting and investment control with respect to the shares held by APNG II. APNG II Management, Mr. Hudson and Mr. Janney disclaim beneficial ownership of all shares held by APNG II, except to the extent of its or their respective pecuniary interests therein. Mr. More is a director of the Issuer and files separate Section 16 reports."}],"balance_after":3924046,"source":{"system":"sec-edgar","filing":"0000899243-21-036429","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036429/doc4.xml","form_type":"4"}},{"id":2644951,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T15:36:48.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":6800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were awarded on June 30, 2021 and vest in equal monthly tranches over a one-year period."}],"balance_after":6800,"derivative":{"exercise_price":68,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":6800},"source":{"system":"sec-edgar","filing":"0001711279-21-000020","document":"wf-form4_162524019238929.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127921000020/wf-form4_162524019238929.xml","form_type":"4"}},{"id":2691097,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-28T20:16:49.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":12376,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares vest in full on the earlier of (i) May 27, 2022 and (ii) the Issuer's next annual meeting of stockholders following May 27, 2021."}],"balance_after":23449,"source":{"system":"sec-edgar","filing":"0001628280-21-011356","document":"wf-form4_162223298726180.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828021011356/wf-form4_162223298726180.xml","form_type":"4"}},{"id":2767764,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-30T18:27:34.000Z","date":"2021-03-26","kind":"sale","acquired":false,"shares":2500,"price":116.09,"value":290225.0,"ownership":{"direct":false,"nature":"By Alta Bioequities L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":56293,"source":{"system":"sec-edgar","filing":"0001209191-21-023622","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919121023622/doc4.xml","form_type":"4"}},{"id":2767763,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-30T18:27:34.000Z","date":"2021-03-26","kind":"sale","acquired":false,"shares":14808,"price":115.01,"value":1703068.08,"ownership":{"direct":false,"nature":"By Alta Bioequities L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.00 - $115.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":58793,"source":{"system":"sec-edgar","filing":"0001209191-21-023622","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919121023622/doc4.xml","form_type":"4"}},{"id":2772991,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-24T19:21:20.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":4118,"price":120.22,"value":495065.96,"ownership":{"direct":false,"nature":"By Alta Bioequities L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.01 - $120.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":73601,"source":{"system":"sec-edgar","filing":"0001209191-21-022932","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919121022932/doc4.xml","form_type":"4"}},{"id":2772990,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-24T19:21:20.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":9030,"price":119.46,"value":1078723.8,"ownership":{"direct":false,"nature":"By Alta Bioequities L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.00 - $119.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":77719,"source":{"system":"sec-edgar","filing":"0001209191-21-022932","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919121022932/doc4.xml","form_type":"4"}},{"id":2785780,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-16T16:17:05.000Z","date":"2021-03-15","kind":"sale","acquired":false,"shares":6708,"price":124.56,"value":835548.48,"ownership":{"direct":false,"nature":"By Alta Bioequities L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.50 - $124.645, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":86749,"source":{"system":"sec-edgar","filing":"0001209191-21-020774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919121020774/doc4.xml","form_type":"4"}},{"id":2785779,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-16T16:17:05.000Z","date":"2021-03-12","kind":"sale","acquired":false,"shares":4071,"price":124.18,"value":505536.78,"ownership":{"direct":false,"nature":"By Alta Bioequities L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.00 - $124.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":93457,"source":{"system":"sec-edgar","filing":"0001209191-21-020774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919121020774/doc4.xml","form_type":"4"}},{"id":2794294,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T19:35:16.000Z","date":"2021-03-11","kind":"sale","acquired":false,"shares":6006,"price":124.62,"value":748467.72,"ownership":{"direct":false,"nature":"By Alta Bioequities L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.25 - $125.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":97528,"source":{"system":"sec-edgar","filing":"0001209191-21-019957","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919121019957/doc4.xml","form_type":"4"}},{"id":2794293,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-11T19:35:16.000Z","date":"2021-03-09","kind":"sale","acquired":false,"shares":100,"price":125,"value":12500.0,"ownership":{"direct":false,"nature":"By Alta Bioequities L.P."},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Shares held prior to the reported transaction consisted of an aggregate of 103,634 shares received in pro rata distributions from APNG I and AP VIII subsequent to the Reporting Person's most recent Section 16 report, which distributions were not required to be reported pursuant to Section 16."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":103534,"source":{"system":"sec-edgar","filing":"0001209191-21-019957","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919121019957/doc4.xml","form_type":"4"}},{"id":3064899,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-08T00:10:36.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":6800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were awarded on June 30, 2020 and vest in equal monthly tranches over a one-year period."}],"balance_after":6800,"derivative":{"exercise_price":41.42,"expiration_date":"2030-06-29","underlying":"Common Stock","underlying_shares":6800},"source":{"system":"sec-edgar","filing":"0000899243-20-021806","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000089924320021806/doc4.xml","form_type":"4"}},{"id":3130535,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T20:40:32.000Z","date":"2018-02-28","kind":"other","acquired":true,"shares":24565,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Alta Bioequities, L.P."},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On February 28, 2018, Alta Partners VIII, L.P. (\"APVIII\") distributed 624,564 shares of Common Stock on a pro rata basis, for no additional consideration, to its partners, which distribution was exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9 and Rule 16a-13. Alta Bioequities, L.P. (\"Alta Bioequities\") received 24,565 of these shares. Alta Bioequities Management, LLC is the general partner of Alta Bioequities L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC and may be deemed to have voting and investment power over the shares owned by Alta Bioequities, L.P."},{"field":"shares","element":"transactionShares","label":"F2","text":"On February 28, 2018, Alta Partners VIII, L.P. (\"APVIII\") distributed 624,564 shares of Common Stock on a pro rata basis, for no additional consideration, to its partners, which distribution was exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9 and Rule 16a-13. Alta Bioequities, L.P. (\"Alta Bioequities\") received 24,565 of these shares. Alta Bioequities Management, LLC is the general partner of Alta Bioequities L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC and may be deemed to have voting and investment power over the shares owned by Alta Bioequities, L.P."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The 24,565 shares of Common Stock reported in this column as indirectly beneficially owned by the Reporting Person through Alta Bioequities were previously reported by the Reporting Person as indirectly beneficially owned through APVIII. These shares became indirectly beneficially owned by the Reporting Person through Alta Bioequities as a result of a pro rata distribution of shares described in footnote (2)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"On February 28, 2018, Alta Partners VIII, L.P. (\"APVIII\") distributed 624,564 shares of Common Stock on a pro rata basis, for no additional consideration, to its partners, which distribution was exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9 and Rule 16a-13. Alta Bioequities, L.P. (\"Alta Bioequities\") received 24,565 of these shares. Alta Bioequities Management, LLC is the general partner of Alta Bioequities L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC and may be deemed to have voting and investment power over the shares owned by Alta Bioequities, L.P."}],"balance_after":24565,"source":{"system":"sec-edgar","filing":"0001179110-20-006718","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000117911020006718/edgar.xml","form_type":"4"}},{"id":3130534,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T20:40:32.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":6106,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares vest in full on the earlier of (i) May 28, 2021 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2020."}],"balance_after":11073,"source":{"system":"sec-edgar","filing":"0001179110-20-006718","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000117911020006718/edgar.xml","form_type":"4"}},{"id":3131916,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-28T16:10:23.000Z","date":"2020-05-26","kind":"grant","acquired":true,"shares":7700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one-year anniversary of the date of grant of the option or (ii) the date of the next annual meeting of stockholders that occurs following the grant of such option, in each case, provided that the Reporting Person continues to serve as a non-employee director through the applicable vesting date."}],"balance_after":7700,"derivative":{"exercise_price":72.54,"expiration_date":"2030-05-26","underlying":"Common Stock","underlying_shares":7700},"source":{"system":"sec-edgar","filing":"0000899243-20-014411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000089924320014411/doc4.xml","form_type":"4"}},{"id":3303106,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":1,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":3,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":4,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":5,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":6,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":7,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":8,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":9,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T18:24:58.000Z","date":"2020-01-22","kind":"other","acquired":true,"shares":6837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Guy P. Nohra in connection with the pro-rata distribution described in footnote (1) herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F9","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Guy P. Nohra in connection with the pro-rata distribution described in footnote (1) herein."}],"balance_after":6837,"source":{"system":"sec-edgar","filing":"0001209191-20-004922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919120004922/doc4.xml","form_type":"4"}},{"id":3303105,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":1,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":3,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":4,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":5,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":6,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":7,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":8,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":9,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T18:24:58.000Z","date":"2020-01-22","kind":"other","acquired":true,"shares":11539,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Alta Bioequities, L.P. in connection with the pro-rata distribution described in footnote (5) herein.  Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Alta Bioequities, L.P. in connection with the pro-rata distribution described in footnote (5) herein.  Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":11539,"source":{"system":"sec-edgar","filing":"0001209191-20-004922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919120004922/doc4.xml","form_type":"4"}},{"id":3303104,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":1,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":3,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":4,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":5,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":6,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":7,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":8,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":9,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T18:24:58.000Z","date":"2020-01-22","kind":"other","acquired":true,"shares":11538,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hudson Capital LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Hudson Capital, LLC, a limited liability company of which Peter A. Hudson is the managing member, in connection with the pro-rata distribution described in footnote (5) herein. Mr. Hudson disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Hudson Capital, LLC, a limited liability company of which Peter A. Hudson is the managing member, in connection with the pro-rata distribution described in footnote (5) herein. Mr. Hudson disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":11538,"source":{"system":"sec-edgar","filing":"0001209191-20-004922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919120004922/doc4.xml","form_type":"4"}},{"id":3303103,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":1,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":3,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":4,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":5,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":6,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":7,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":8,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":9,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T18:24:58.000Z","date":"2020-01-22","kind":"other","acquired":true,"shares":11538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Robert J. More in connection with the pro-rata distribution described in footnote (5) herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Robert J. More in connection with the pro-rata distribution described in footnote (5) herein."}],"balance_after":11538,"source":{"system":"sec-edgar","filing":"0001209191-20-004922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919120004922/doc4.xml","form_type":"4"}},{"id":3303102,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":1,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":3,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":4,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":5,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":6,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":7,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":8,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":9,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T18:24:58.000Z","date":"2020-01-22","kind":"other","acquired":false,"shares":34615,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By APNG I Management"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by APNG I Management, without consideration, to its members."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-004922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919120004922/doc4.xml","form_type":"4"}},{"id":3303101,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":1,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":3,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":4,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":5,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":6,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":7,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":8,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":9,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T18:24:58.000Z","date":"2020-01-22","kind":"other","acquired":true,"shares":34615,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By APNG I Management"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Alta Partners NextGen Fund I L.P. (\"APNG I\"), without consideration, to its general partner and limited partners."}],"balance_after":34615,"source":{"system":"sec-edgar","filing":"0001209191-20-004922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919120004922/doc4.xml","form_type":"4"}},{"id":3303100,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":1,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":3,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":4,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":5,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":6,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":7,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":8,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":9,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T18:24:58.000Z","date":"2020-01-22","kind":"other","acquired":false,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Alta Partners NextGen Fund I L.P. (\"APNG I\"), without consideration, to its general partner and limited partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 2,557,377 shares held of record by APNG I and 7,961,823 shares held of record by Alta Partners VIII, L.P. (\"Alta VIII\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares directly held by Alta VIII are indirectly held by Alta Partners Management VIII, LLC (\"Alta Management VIII\"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares directly held by APNG I are indirectly held by Alta Partners NextGen Fund I Management, LLC (\"APNG I Management\"), which is the general partner of APNG I. The individual managing directors of APNG I Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG I Management exercise sole voting and investment control with respect to the shares held by APNG I. The individual managing directors of APNG I Management disclaim beneficial ownership of all shares held by APNG I, except to the extent of their respective pecuniary interests therein."}],"balance_after":10519200,"source":{"system":"sec-edgar","filing":"0001209191-20-004922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919120004922/doc4.xml","form_type":"4"}},{"id":3425045,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-03T21:23:49.000Z","date":"2019-08-30","kind":"sale","acquired":false,"shares":32190,"price":46.18,"value":1486534.2,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades ranging from $46.03 to $46.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Directly beneficially owned by Alta Bioequities, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The reporting person is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":366362,"source":{"system":"sec-edgar","filing":"0001209191-19-048011","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000120919119048011/doc4.xml","form_type":"4"}},{"id":3425044,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-03T21:23:49.000Z","date":"2019-08-29","kind":"sale","acquired":false,"shares":700,"price":47.5,"value":33250.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades ranging from $47.43 to $47.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Directly beneficially owned by Alta Bioequities, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The reporting person is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":398552,"source":{"system":"sec-edgar","filing":"0001209191-19-048011","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000120919119048011/doc4.xml","form_type":"4"}},{"id":3425043,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-03T21:23:49.000Z","date":"2019-08-29","kind":"sale","acquired":false,"shares":55794,"price":46.61,"value":2600558.34,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades ranging from $46.43 to $47.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Directly beneficially owned by Alta Bioequities, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The reporting person is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":399252,"source":{"system":"sec-edgar","filing":"0001209191-19-048011","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000120919119048011/doc4.xml","form_type":"4"}},{"id":3483856,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2019-06-19T17:51:09.000Z","date":"2019-06-17","kind":"grant","acquired":true,"shares":11610,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12th of the total shares monthly, beginning on July 7, 2019, with 100% of the total shares vested and exercisable on June 7, 2020, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":11610,"derivative":{"exercise_price":11.12,"expiration_date":"2029-06-16","underlying":"Common Stock","underlying_shares":11610},"source":{"system":"sec-edgar","filing":"0001209191-19-038100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919119038100/doc4.xml","form_type":"4"}},{"id":3493869,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-11T16:26:34.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one-year anniversary of the date of grant of the annual option or (ii) the date of the next annual meeting of stockholders that occurs following the grant of such annual option, in each case, provided that the Reporting Person continues to serve as a non-employee director through the applicable vesting date."}],"balance_after":16000,"derivative":{"exercise_price":40,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000899243-19-016377","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000089924319016377/doc4.xml","form_type":"4"}},{"id":3506263,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-31T20:51:41.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":4967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares vest in full on the earlier of (i) May 29, 2020 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2019."}],"balance_after":4967,"source":{"system":"sec-edgar","filing":"0001179110-19-006917","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000117911019006917/edgar.xml","form_type":"4"}},{"id":3506262,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-31T20:51:41.000Z","date":"2018-02-28","kind":"other","acquired":true,"shares":24565,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Alta Bioequities, L.P."},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On February 28, 2018, Alta Partners VIII, L.P. (\"APVIII\") distributed 624,564 shares of Common Stock on a pro rata basis, for no additional consideration, to its partners, which distribution was exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9 and Rule 16a-13.  Alta Bioequities, L.P. (\"Alta Bioequities\") received 24,565 of these shares.  Alta Bioequities Management, LLC is the general partner of Alta Bioequities L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC and may be deemed to have voting and investment power over the shares owned by Alta Bioequities, L.P."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 28, 2018, Alta Partners VIII, L.P. (\"APVIII\") distributed 624,564 shares of Common Stock on a pro rata basis, for no additional consideration, to its partners, which distribution was exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9 and Rule 16a-13.  Alta Bioequities, L.P. (\"Alta Bioequities\") received 24,565 of these shares.  Alta Bioequities Management, LLC is the general partner of Alta Bioequities L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC and may be deemed to have voting and investment power over the shares owned by Alta Bioequities, L.P."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The 24,565 shares of Common Stock reported in this column as indirectly beneficially owned by the Reporting Person through Alta Bioequities were previously reported by the Reporting Person as indirectly beneficially owned through APVIII. These shares became indirectly beneficially owned by the Reporting Person through Alta Bioequities as a result of a pro rata distribution of shares described in footnote (1)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On February 28, 2018, Alta Partners VIII, L.P. (\"APVIII\") distributed 624,564 shares of Common Stock on a pro rata basis, for no additional consideration, to its partners, which distribution was exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9 and Rule 16a-13.  Alta Bioequities, L.P. (\"Alta Bioequities\") received 24,565 of these shares.  Alta Bioequities Management, LLC is the general partner of Alta Bioequities L.P.  The Reporting Person is the Managing Director of Alta Bioequities Management, LLC and may be deemed to have voting and investment power over the shares owned by Alta Bioequities, L.P."}],"balance_after":24565,"source":{"system":"sec-edgar","filing":"0001179110-19-006917","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000117911019006917/edgar.xml","form_type":"4"}},{"id":3715070,"issuer":{"id":11899,"kind":"organization","name":"VIVEVE MEDICAL, INC.","symbol":"VIVE"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-01-02T15:48:42.000Z","date":"2018-12-31","kind":"grant","acquired":true,"shares":21131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the \"Plan\") and received a restricted stock award of 21,131 shares of common stock on December 31, 2018 (the \"Grant Date\").  The restricted stock award shall vest in full on the Grant Date."}],"balance_after":60579,"source":{"system":"sec-edgar","filing":"0001437749-19-000069","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879682/000143774919000069/rdgdoc.xml","form_type":"4"}},{"id":3783681,"issuer":{"id":11899,"kind":"organization","name":"VIVEVE MEDICAL, INC.","symbol":"VIVE"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true}}],"security":"Non-qualified Stock Option (Right to Purchase)","published_at":"2018-10-25T12:48:15.000Z","date":"2018-10-23","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the \"Plan\") and received 17,500 non-qualified stock options on October 23, 2018 (the \"Grant Date\"). The non-qualified stock options shall vest in full on May 22, 2019"}],"balance_after":17500,"derivative":{"exercise_price":3.47,"expiration_date":"2028-10-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001437749-18-018775","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879682/000143774918018775/rdgdoc.xml","form_type":"4"}},{"id":3797534,"issuer":{"id":11899,"kind":"organization","name":"VIVEVE MEDICAL, INC.","symbol":"VIVE"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-10-04T13:17:37.000Z","date":"2018-10-01","kind":"grant","acquired":true,"shares":8947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the \"Plan\") and received a restricted stock award of 8,947 shares of common stock on October 1, 2018 (the \"Grant Date\").  The restricted stock award shall vest in full on the Grant Date."}],"balance_after":39448,"source":{"system":"sec-edgar","filing":"0001437749-18-017961","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879682/000143774918017961/rdgdoc.xml","form_type":"4"}},{"id":3804116,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Preferred Stock","published_at":"2018-10-01T17:18:27.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":18698578,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Alta Partners VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Alta Partners VIII, L.P. (\"Alta Partners).  Alta Partners Management VIII, LLC (\"Alta Management\") is the general partner of Alta Partners.  The reporting person, a member of the issuer's board of directors, is a managing director of Alta Management, and may be deemed to share voting and investment power over the securities held by Alta Partners.  The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":514211},"source":{"system":"sec-edgar","filing":"0001209191-18-052839","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919118052839/doc4.xml","form_type":"4"}},{"id":3804115,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2018-10-01T17:18:27.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":9449318,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Alta Partners VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Alta Partners VIII, L.P. (\"Alta Partners).  Alta Partners Management VIII, LLC (\"Alta Management\") is the general partner of Alta Partners.  The reporting person, a member of the issuer's board of directors, is a managing director of Alta Management, and may be deemed to share voting and investment power over the securities held by Alta Partners.  The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":382698},"source":{"system":"sec-edgar","filing":"0001209191-18-052839","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919118052839/doc4.xml","form_type":"4"}},{"id":3804114,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-10-01T17:18:27.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":12387324,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Alta Partners VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Alta Partners VIII, L.P. (\"Alta Partners).  Alta Partners Management VIII, LLC (\"Alta Management\") is the general partner of Alta Partners.  The reporting person, a member of the issuer's board of directors, is a managing director of Alta Management, and may be deemed to share voting and investment power over the securities held by Alta Partners.  The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":458331},"source":{"system":"sec-edgar","filing":"0001209191-18-052839","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919118052839/doc4.xml","form_type":"4"}},{"id":3804113,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-10-01T17:18:27.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":10201769,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Alta Partners VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Alta Partners VIII, L.P. (\"Alta Partners).  Alta Partners Management VIII, LLC (\"Alta Management\") is the general partner of Alta Partners.  The reporting person, a member of the issuer's board of directors, is a managing director of Alta Management, and may be deemed to share voting and investment power over the securities held by Alta Partners.  The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":589661},"source":{"system":"sec-edgar","filing":"0001209191-18-052839","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919118052839/doc4.xml","form_type":"4"}},{"id":3804112,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:18:27.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":514211,"ownership":{"direct":false,"nature":"By Alta Partners VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Alta Partners VIII, L.P. (\"Alta Partners).  Alta Partners Management VIII, LLC (\"Alta Management\") is the general partner of Alta Partners.  The reporting person, a member of the issuer's board of directors, is a managing director of Alta Management, and may be deemed to share voting and investment power over the securities held by Alta Partners.  The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1944901,"source":{"system":"sec-edgar","filing":"0001209191-18-052839","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919118052839/doc4.xml","form_type":"4"}},{"id":3804111,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:18:27.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":382698,"ownership":{"direct":false,"nature":"By Alta Partners VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Alta Partners VIII, L.P. (\"Alta Partners).  Alta Partners Management VIII, LLC (\"Alta Management\") is the general partner of Alta Partners.  The reporting person, a member of the issuer's board of directors, is a managing director of Alta Management, and may be deemed to share voting and investment power over the securities held by Alta Partners.  The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1430690,"source":{"system":"sec-edgar","filing":"0001209191-18-052839","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919118052839/doc4.xml","form_type":"4"}},{"id":3804110,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:18:27.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":458331,"ownership":{"direct":false,"nature":"By Alta Partners VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Alta Partners VIII, L.P. (\"Alta Partners).  Alta Partners Management VIII, LLC (\"Alta Management\") is the general partner of Alta Partners.  The reporting person, a member of the issuer's board of directors, is a managing director of Alta Management, and may be deemed to share voting and investment power over the securities held by Alta Partners.  The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1047992,"source":{"system":"sec-edgar","filing":"0001209191-18-052839","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919118052839/doc4.xml","form_type":"4"}},{"id":3804109,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:18:27.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":589661,"ownership":{"direct":false,"nature":"By Alta Partners VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Alta Partners VIII, L.P. (\"Alta Partners).  Alta Partners Management VIII, LLC (\"Alta Management\") is the general partner of Alta Partners.  The reporting person, a member of the issuer's board of directors, is a managing director of Alta Management, and may be deemed to share voting and investment power over the securities held by Alta Partners.  The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":589661,"source":{"system":"sec-edgar","filing":"0001209191-18-052839","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919118052839/doc4.xml","form_type":"4"}},{"id":3804124,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":1,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":3,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":4,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":5,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Preferred Stock","published_at":"2018-10-01T17:12:29.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":18698578,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares directly held by Alta Partners VIII, L.P. (\"Alta VIII\") are indirectly held by Alta Partners Management VIII, LLC (\"Alta Management VIII\"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":514211},"source":{"system":"sec-edgar","filing":"0001209191-18-052831","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1198321/000120919118052831/doc4.xml","form_type":"4"}},{"id":3804123,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":1,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":3,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":4,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":5,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2018-10-01T17:12:29.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":9449318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares directly held by Alta Partners VIII, L.P. (\"Alta VIII\") are indirectly held by Alta Partners Management VIII, LLC (\"Alta Management VIII\"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":382698},"source":{"system":"sec-edgar","filing":"0001209191-18-052831","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1198321/000120919118052831/doc4.xml","form_type":"4"}},{"id":3804122,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":1,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":3,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":4,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":5,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-10-01T17:12:29.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":12387324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares directly held by Alta Partners VIII, L.P. (\"Alta VIII\") are indirectly held by Alta Partners Management VIII, LLC (\"Alta Management VIII\"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":458331},"source":{"system":"sec-edgar","filing":"0001209191-18-052831","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1198321/000120919118052831/doc4.xml","form_type":"4"}},{"id":3804121,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":1,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":3,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":4,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":5,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-10-01T17:12:29.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":10201769,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares directly held by Alta Partners VIII, L.P. (\"Alta VIII\") are indirectly held by Alta Partners Management VIII, LLC (\"Alta Management VIII\"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":589661},"source":{"system":"sec-edgar","filing":"0001209191-18-052831","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1198321/000120919118052831/doc4.xml","form_type":"4"}},{"id":3804120,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":1,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":3,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":4,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":5,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:12:29.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":514211,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares directly held by Alta Partners VIII, L.P. (\"Alta VIII\") are indirectly held by Alta Partners Management VIII, LLC (\"Alta Management VIII\"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein."}],"balance_after":1944901,"source":{"system":"sec-edgar","filing":"0001209191-18-052831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1198321/000120919118052831/doc4.xml","form_type":"4"}},{"id":3804119,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":1,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":3,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":4,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":5,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:12:29.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":382698,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares directly held by Alta Partners VIII, L.P. (\"Alta VIII\") are indirectly held by Alta Partners Management VIII, LLC (\"Alta Management VIII\"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein."}],"balance_after":1430690,"source":{"system":"sec-edgar","filing":"0001209191-18-052831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1198321/000120919118052831/doc4.xml","form_type":"4"}},{"id":3804118,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":1,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":3,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":4,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":5,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:12:29.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":458331,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares directly held by Alta Partners VIII, L.P. (\"Alta VIII\") are indirectly held by Alta Partners Management VIII, LLC (\"Alta Management VIII\"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein."}],"balance_after":1047992,"source":{"system":"sec-edgar","filing":"0001209191-18-052831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1198321/000120919118052831/doc4.xml","form_type":"4"}},{"id":3804117,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":1,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":3,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":4,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":5,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:12:29.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":589661,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares directly held by Alta Partners VIII, L.P. (\"Alta VIII\") are indirectly held by Alta Partners Management VIII, LLC (\"Alta Management VIII\"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein."}],"balance_after":589661,"source":{"system":"sec-edgar","filing":"0001209191-18-052831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1198321/000120919118052831/doc4.xml","form_type":"4"}},{"id":3806474,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":1,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2018-09-27T17:56:55.000Z","date":"2018-09-26","kind":"grant","acquired":true,"shares":26033,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 2.778% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2021, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":26033,"derivative":{"exercise_price":15,"expiration_date":"2028-09-25","underlying":"Common Stock","underlying_shares":26033},"source":{"system":"sec-edgar","filing":"0001209191-18-052483","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1198325/000120919118052483/doc4.xml","form_type":"4"}}],"next_cursor":"2018-09-27T17:56:55.000000Z,3806474"}